The new NGS Partner Enablement Program aims to bridge the gap between assay developers and laboratory infrastructure. By creating a standardized framework, MGI seeks to reduce the time required to implement regulated clinical workflows. Fang Chen, General Manager for Europe and Africa, noted that the initiative is designed to unify software providers, automation partners, and clinicians under a single ecosystem to accelerate high-quality genomic testing.

Simultaneously, the company is expanding its OEM framework to include the D16 library preparation system. Set for release later this year, the D16 is an upgraded, mid-throughput successor to the D4, featuring a single-channel robotic pipetting module and a fully enclosed contamination control system. According to OEM Director Wim Vervaeke, this hardware, when bundled with the E25 sequencing platform, creates a "walkaway" solution intended to automate complex tasks without manual intervention.

Beyond hardware, MGI hosted a satellite symposium detailing the translation of spatial multi-omics into clinical practice. Experts from IPATIMUP, University Hospital Schleswig-Holstein, and BMR Genomics presented data on gene fusion detection and tumor microenvironment mapping, illustrating how these tools are currently applied in oncology and pharmacogenomics. With 27 units of its ultra-high-throughput T7+ platform already installed globally, MGI is positioning its diverse product range—from benchtop systems to large-scale sequencers—to capture a larger share of Europe’s precision medicine market.